Literature DB >> 9435862

Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein.

B Gerstmayer1, M Hoffmann, U Altenschmidt, W Wels.   

Abstract

T cells require at least two signals for activation and clonal expansion. The first signal conferring specificity is initiated by interaction of the T cell receptor with peptide-bearing MHC molecules. The second, costimulatory signal can be provided by cell-surface molecules on antigen-presenting cells such as B7-1 (CD80) and B7-2 (CD86), which interact with CD28 on T cells. To direct the costimulatory B7-2 molecule to the surface of tumor cells we have constructed a chimeric fusion protein, which consists of the extracellular domain of human B7-2 fused to a single-chain antibody domain (scFv) specific for the ErbB2 protein, a type I growth factor receptor overexpressed in a high percentage of human adenocarcinomas. This B7-2(225)-scFv(FRP5) molecule, expressed in the yeast Pichia pastoris and purified from culture supernatants, binds to B7 counter-receptors and to ErbB2. B7-2(225)-scFv(FRP5) localizes specifically to the surface of ErbB2-expressing target cells, thereby providing a costimulatory signal, which results in enhanced proliferation of syngeneic T cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9435862     DOI: 10.1007/s002620050421

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  3 in total

1.  IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

Authors:  Robin Parihar; Julie Dierksheide; Yan Hu; William E Carson
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 2.  Molecular farming of pharmaceutical proteins.

Authors:  R Fischer; N Emans
Journal:  Transgenic Res       Date:  2000       Impact factor: 3.145

Review 3.  Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.

Authors:  Ke-Jia Hu; Elaine Tan Su Yin; Yong-Xian Hu; He Huang
Journal:  Curr Med Sci       Date:  2021-07-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.